Effects of mannose-binding lectin polymorphisms on irinotecan-induced febrile neutropenia

Oncologist

Volumn 15, Issue 10, 2010, Pages 1063-1072

  van der Bol, Jessica M ^a   de Jong, Floris A ^a   van Schaik, Ron H ^b   Sparreboom, Alex ^a,c   van Fessem, Marianne A ^b   van de Geijn, Fleur E ^a   van Daele, Paul L ^a   Verweij, Jaap ^a   Sleijfer, Stefan ^a   Mathijssen, Ron H ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b Department of Clinical Chemistry ^*  (Netherlands)

^c ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

Febrile neutropenia; Genotypes; Irinotecan; MBL; Polymorphisms; Toxicity

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; ARGININE; ASPARTIC ACID; CYSTEINE; GLUTAMIC ACID; GLYCINE; IRINOTECAN; MANNOSE BINDING LECTIN; NEOMYCIN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER OF UNKNOWN PRIMARY SITE; CHOROID MELANOMA; COLORECTAL CANCER; CONTROLLED STUDY; DIGESTIVE SYSTEM CANCER; EXON; FEBRILE NEUTROPENIA; FEMALE; FEVER; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HAPLOTYPE; HEAD AND NECK CANCER; HUMAN; INCIDENCE; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MEDULLOBLASTOMA; NEUTROPENIA; OVARY CARCINOMA; PHENOTYPE; PRIORITY JOURNAL; PROMOTER REGION; RISK FACTOR; SARCOMA; UROGENITAL TRACT CANCER; UTERINE CERVIX CARCINOMA; WILD TYPE;

ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; FEMALE; FEVER; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HAPLOTYPES; HUMANS; MALE; MANNOSE-BINDING LECTIN; MIDDLE AGED; NEOPLASMS; NEUTROPENIA; POLYMORPHISM, GENETIC; PROMOTER REGIONS, GENETIC;

EID: 78049283943     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2010-0033     Document Type: Article

References (50)

1. Eisen DP, Minchinton RM. Impact of mannose-binding lectin on susceptibility to infectious diseases. Clin Infect Dis 2003;37:1496-1505.
2. Ip WK, Takahashi K, Ezekowitz RA et al. Mannose-binding lectin and innate immunity. Immunol Rev 2009;230:9-21.
3. Tsutsumi A, Takahashi R, Sumida T. Mannose binding lectin: Genetics and autoimmune disease. Autoimmun Rev 2005;4:364-372.
4. Holmskov U, Malhotra R, Sim RB et al. Collectins: Collagenous C-type lectins of the innate immune defense system. Immunol Today 1994;15:67-74.
5. Dommett RM, Klein N, Turner MW. Mannose-binding lectin in innate immunity: Past, present and future. Tissue Antigens 2006;68:193-209.
6. Mullighan CG, Bardy PG. Mannose-binding lectin and infection following allogeneic hemopoietic stem cell transplantation. Leuk Lymphoma 2004; 45:247-256.
7. Mullighan CG, Heatley S, Doherty K et al. Mannose-binding lectin genepolymorphisms are associated with major infection following allogeneic hemopoietic stem cell transplantation. Blood 2002;99:3524-3529.
8. Mullighan CG, Heatley SL, Danner S et al. Mannose-binding lectin status is associated with risk of major infection following myeloablative sibling allogeneic hematopoietic stem cell transplantation. Blood 2008;112:2120-2128.
9. Neth O, Hann I, Turner MW et al. Deficiency of mannose-binding lectin and burden of infection in children with malignancy: A prospective study.Lancet 2001;358:614-618.
10. Schlapbach LJ, Aebi C, Otth M et al. Serum levels of mannose-binding lectin and the risk of fever in neutropenia pediatric cancer patients. Pediatr Blood Cancer 2007;49:11-16.
11. Vekemans M, Robinson J, Georgala A et al. Low mannose-binding lectin concentration is associated with severe infection in patients with hematological cancer who are undergoing chemotherapy. Clin Infect Dis 2007;44:1593-1601.
12. Bergmann OJ, Christiansen M, Laursen I et al. Low levels of mannosebinding lectin do not affect occurrence of severe infections or duration of fever in acute myeloid leukaemia during remission induction therapy. Eur J Haematol 2003;70:91-97.
13. Kilpatrick DC, McLintock LA, Allan EK et al. No strong relationship between mannan binding lectin or plasma ficolins and chemotherapyrelated infections. Clin Exp Immunol 2003;134:279-284.
14. Mølle I, Steffensen R, Thiel S et al. Chemotherapy-related infections in patients with multiple myeloma: Associations with mannan-binding lectin genotypes. Eur J Haematol 2006;77:19-26.
15. Peterslund NA, Koch C, Jensenius JC et al. Association between deficiency of mannose-binding lectin and severe infections after chemotherapy. Lancet 2001;358:637-638.
16. Rocha V, Franco RF, Porcher R et al. Host defense and inflammatory gene polymorphisms are associated with outcomes after HLA-identical sibling bone marrow transplantation. Blood 2002;100:3908-3918.
17. Lipscombe RJ, Sumiya M, Hill AV et al. High frequencies in African and non-African populations of independent mutations in the mannose binding protein gene. Hum Mol Genet 1992;1:709-715.
18. Madsen HO, Garred P, Thiel S et al. Interplay between promoter and structural gene variants control basal serum level of mannan-binding protein. J Immunol 1995;155:3013-3020.
19. Sastry K, Herman GA, Day L et al. The human mannose-binding protein gene. Exon structure reveals its evolutionary relationship to a human pulmonary surfactant gene and localization to chromosome 10. J Exp Med 1989;170:1175-1189.
20. Turner MW. Mannose-binding lectin (MBL) in health and disease. Immunobiology 1998;199:327-339.
21. Steffensen R, Thiel S, Varming K et al. Detection of structural gene mutations and promoter polymorphisms in the mannan-binding lectin (MBL) gene by polymerase chain reaction with sequence-specific primers. J Immunol Methods 2000;241:33-42.
22. Madsen HO, Garred P, Kurtzhals JA et al. A new frequent allele is the missing link in the structural polymorphism of the human mannanbinding protein. Immunogenetics 1994;40:37-44.
23. Mead R, Jack D, Pembrey M et al. Mannose-binding lectin alleles in a prospectively recruited UK population. The ALSPAC Study Team. Avon Longitudinal Study of Pregnancy and Childhood. Lancet 1997; 349:1669-1670.
24. Minchinton RM, Dean MM, Clark TR et al. Analysis of the relationship between mannose-binding lectin (MBL) genotype, MBL levels and function in an Australian blood donor population. Scand J Immunol 2002;56:630-641.
25. Cunningham D, Pyrhönen S, James RD et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 1998;352:1413-1418.
26. Rougier P, Van Cutsem E, Bajetta E et al. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 1998;352:1407-1412.
27. de Jong FA, van der Bol JM, Mathijssen RH et al. Renal function as a predictor of irinotecan-induced neutropenia. Clin Pharmacol Ther 2008; 84:254-262.
28. Innocenti F, Kroetz DL, Schuetz E et al. Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics. J Clin Oncol 2009;27:2604-2614.
29. Kehrer DF, Mathijssen RH, Verweij J et al. Modulation of irinotecan metabolism by ketoconazole. J Clin Oncol 2002;20:3122-3129.
30. Rosner GL, Panetta JC, Innocenti F et al. Pharmacogenetic pathway analysis of irinotecan. Clin Pharmacol Ther 2008;84:393-402.
31. van der Bol JM, Mathijssen RH, Loos WJ et al. Cigarette smoking and irinotecan treatment: Pharmacokinetic interaction and effects on neutropenia. J Clin Oncol 2007;25:2719-2726.
32. de Jong FA, Mathijssen RH, Xie R et al. Flat-fixed dosing of irinotecan: Influence on pharmacokinetic and pharmacodynamic variability. Clin Cancer Res 2004;10:4068-4071.
33. Mathijssen RH, Verweij J, de Jonge MJ et al. Impact of body-size measures on irinotecan clearance: Alternative dosing recommendations. J Clin Oncol 2002;20:81-87.
34. van der Bol JM, Mathijssen RH, Creemers GJ et al. A CYP3A4 phenotype- based dosing algorithm for individualized treatment of irinotecan.Clin Cancer Res 2010;16:736-742.
35. de Jong FA, Kehrer DF, Mathijssen RH et al. Prophylaxis of irinotecaninduced diarrhea with neomycin and potential role for UGT1A1 28 genotype screening: A double-blind, randomized, placebo-controlled study. The Oncologist 2006;11:944-954.
36. Engels FK, de Jong FA, Sparreboom A et al. Medicinal cannabis does not influence the clinical pharmacokinetics of irinotecan and docetaxel. The Oncologist 2007;12:291-300.
37. Mathijssen RH, de Jong FA, van Schaik RH et al. Prediction of irinotecan pharmacokinetics by use of cytochrome P450 3A4 phenotyping probes. J Natl Cancer Inst 2004;96:1585-1592.
38. Goodman CS, Limbird CE, Milinoff PB et al., eds. The Pharmacological Basis of herapeutics, Antimicrobial Agents, Neomycin, Eighth Edition. Columbus, OH: McGraw-Hill, Inc., 1990:1112-1113.
39. Mullighan CG, Marshall SE, Welsh KI. Mannose binding lectin polymorphisms are associated with early age of disease onset and autoimmunity in common variable immunodeficiency. Scand J Immunol 2000; 51:111-122.
40. Sullivan KE, Wooten C, Goldman D et al. Mannose-binding protein genetic polymorphisms in black patients with systemic lupus erythematosus. Arthritis Rheum 1996;39:2046-2051.
41. Innocenti F, Undevia SD, Iyer L et al. Genetic variants in the UDPglucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol 2004;22:1382- 1388.
42. Madsen HO, Videm V, Svejgaard A et al. Association of mannosebinding-lectin deficiency with severe atherosclerosis. Lancet 1998;352: 959-960.
43. Pine SR, Mechanic LE, Ambs S et al. Lung cancer survival and functional polymorphisms in MBL2, an innate-immunity gene. J Natl Cancer Inst 2007;99:1401-1409.
44. Freifeld A, Marchigiani D, Walsh T et al. A double-blind comparison of empirical oral and intravenous antibiotic therapy for low-risk febrile patients with neutropenia during cancer chemotherapy. N Engl J Med 1999;341:305-311.
45. Slobbe L, Waal L, Jongman LR et al. Three-day treatment with imipenem for unexplained fever during prolonged neutropaenia in haematology patients receiving fluoroquinolone and fluconazole prophylaxis: A prospective observational safety study. Eur J Cancer 009;45:2810-2817.
46. Schafranski MD, Stier A, Nisihara R et al. Significantly increased levels of mannose-binding lectin (MBL) in rheumatic heart disease: A beneficial role for MBL deficiency. Clin Exp Immunol 2004;138:521-525.
47. Sharma A, Lokeshwar N. Febrile neutropenia in haematological malignancies. J Postgrad Med 2005;51(suppl 1):S42-S48.
48. Klostergaard A, Steffensen R, Møller JK et al. Sepsis in acute myeloid leukaemia patients receiving high-dose chemotherapy: No impact of chitotriosidase and mannose-binding lectin polymorphisms. Eur J Haematol 2010;85:58-64.
49. Frakking FN, van de Wetering MD, Brouwer N et al. The role of mannose- binding lectin (MBL) in paediatric oncology patients with febrile neutropenia. Eur J Cancer 2006;42:909-916.
50. Frakking FN, Brouwer N, van de Wetering MD et al. Safety and pharmacokinetics of plasma-derived mannose-binding lectin (MBL) substitutionin children with chemotherapy-induced neutropaenia. Eur J Cancer 2009;45:505-512.